↓ Skip to main content

The basics of preclinical drug development for neurodegenerative disease indications

Overview of attention for article published in BMC Neurology, January 2009
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (91st percentile)

Mentioned by

news
1 news outlet
policy
1 policy source
twitter
2 tweeters

Citations

dimensions_citation
51 Dimensions

Readers on

mendeley
355 Mendeley
citeulike
2 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The basics of preclinical drug development for neurodegenerative disease indications
Published in
BMC Neurology, January 2009
DOI 10.1186/1471-2377-9-s1-s2
Pubmed ID
Authors

Karen L Steinmetz, Edward G Spack

Abstract

Preclinical development encompasses the activities that link drug discovery in the laboratory to initiation of human clinical trials. Preclinical studies can be designed to identify a lead candidate from several hits; develop the best procedure for new drug scale-up; select the best formulation; determine the route, frequency, and duration of exposure; and ultimately support the intended clinical trial design. The details of each preclinical development package can vary, but all have some common features. Rodent and nonrodent mammalian models are used to delineate the pharmacokinetic profile and general safety, as well as to identify toxicity patterns. One or more species may be used to determine the drug's mean residence time in the body, which depends on inherent absorption, distribution, metabolism, and excretion properties. For drugs intended to treat Alzheimer's disease or other brain-targeted diseases, the ability of a drug to cross the blood brain barrier may be a key issue. Toxicology and safety studies identify potential target organs for adverse effects and define the Therapeutic Index to set the initial starting doses in clinical trials. Pivotal preclinical safety studies generally require regulatory oversight as defined by US Food and Drug Administration (FDA) Good Laboratory Practices and international guidelines, including the International Conference on Harmonization. Concurrent preclinical development activities include developing the Clinical Plan and preparing the new drug product, including the associated documentation to meet stringent FDA Good Manufacturing Practices regulatory guidelines. A wide range of commercial and government contract options are available for investigators seeking to advance their candidate(s). Government programs such as the Small Business Innovative Research and Small Business Technology Transfer grants and the National Institutes of Health Rapid Access to Interventional Development Pilot Program provide funding and services to assist applicants in preparing the preclinical programs and documentation for their drugs. Increasingly, private foundations are also funding preclinical work. Close interaction with the FDA, including a meeting to prepare for submission of an Investigational New Drug application, is critical to ensure that the preclinical development package properly supports the planned phase I clinical trial.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 355 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 3 <1%
United Kingdom 1 <1%
Germany 1 <1%
Unknown 350 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 74 21%
Student > Master 63 18%
Student > Bachelor 58 16%
Student > Ph. D. Student 31 9%
Other 30 8%
Other 41 12%
Unknown 58 16%
Readers by discipline Count As %
Agricultural and Biological Sciences 68 19%
Pharmacology, Toxicology and Pharmaceutical Science 54 15%
Medicine and Dentistry 41 12%
Biochemistry, Genetics and Molecular Biology 39 11%
Chemistry 27 8%
Other 53 15%
Unknown 73 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 July 2021.
All research outputs
#1,766,591
of 18,763,644 outputs
Outputs from BMC Neurology
#157
of 2,027 outputs
Outputs of similar age
#11,766
of 137,060 outputs
Outputs of similar age from BMC Neurology
#1
of 1 outputs
Altmetric has tracked 18,763,644 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,027 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 137,060 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them